We modified the existing drug structure by adding the albumin-binding motifs Lys(-4-TBA)-6-AMBA(INER-PP-F11N-1) or Lys(-4-TBA)-6-AHA(INER-PP-F11N-2) to reduce accumulation in non-target organs and enhance tumor-targeting efficacy (Figure 1). The gene discussed is ALB; the disease is neoplasm.